Edgar Filing: ACCELERON PHARMA INC - Form 4

ACCELERO Form 4 July 16, 2015	N PHARMA INC	2									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								-	PPROVAL 3235-0287		
Check this if no long subject to Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	s box s box s box s STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF S SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, s Section 17(a) of the Public Utility Holding Company Act of 1935 or Section a 20(b) of the Investment Company Act of 1040								Expires: Estimated a burden hou response	January 31	
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Quisel John D			2. Issuer Name and Ticker or Trading Symbol ACCELERON PHARMA INC [XLRN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
128 SIDNEY STREET (Month/D) (Street) 4. If Ame			3. Date of Earliest Transaction(Month/Day/Year)07/14/2015					Director 10% Owner X Officer (give title Other (specify below) below) SVP Gen. Counsel & Secretary			
			Amendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person				
CAMBRIDO	GE, MA 02139							Form filed by M Person	Iore than One Re	eporting	
(City)	(State) (Zip)	Table	e I - Non-De	erivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any	n Date, if	3. Transactio Code (Instr. 8)	n(A) or Di (D) (Instr. 3,	4 and (A) or	d of 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial	
Common Stock	07/14/2015			Code V M <u>(1)</u>	Amount 5,500	(D) A	Price \$ 5.88	28,201	D		
Common Stock	07/14/2015			S <u>(1)</u>	5,500	D	\$ 30	22,701	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: ACCELERON PHARMA INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. D Se (Ii
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Option to Purchase Common Stock	\$ 5.88	07/14/2015	M <u>(1)</u>	5,500	(2)	12/02/2019	Common Stock	5,500	

Reporting Owners

Reporting Owner Name / Address	Relationships						
1 8	Director	10% Owner	Officer	Other			
Quisel John D 128 SIDNEY STREET CAMBRIDGE, MA 02139			SVP Gen. Counsel & Secretary				

Signatures

Reporting Person

/s/ John D. 07/16/2015 Ouisel **Signature of Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (2) The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.